CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Genetic & Molecular Testing — Proprietary / Investigational Laboratory Tests Coverage

Defines coverage stance for a list of proprietary genetic and molecular diagnostic, prognostic, and risk-assessment tests for Medicare Advantage and Commercial products of Blue Cross Blue Shield - Rhode Island.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyGenetic & Molecular Testing — Proprietary / Investigational Laboratory Tests Coverage

Policy CodePolicy N/A

Change TypeNo material change

Effective DateJan 1, 2024

Next Review DateN/A

Key ActionVerify member-specific benefits and prior authorization requirements with the payer before billing; benefits may vary by contract.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

10+named tests considered not covered / not medically necessary

9 PLA codesPLA / CPT codes provided

Medicare + Commercialpayers / products addressed

CLIA high-complexitylab regulatory expectation

0415UNew CPT code referenced

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage criteria and investigational determinations

Investigational / Not Medically Necessary Tests

Not covered / Not medically necessary

General policy stance: The listed genetic and molecular tests are considered investigational and are not covered for Medicare Advantage Plans and are not medically necessary for Commercial Products due to insufficient evidence of clinical utility.

If a separate evidence review exists for a test, that review supersedes this policy.

Tests considered investigational / not medically necessary: Polygenic Risk Score; Thyroid GuidePx; Apolipoprotein L1 (APOL1) renal risk variant genotyping; Oncuria Monitor; Oncuria Detect; Oncuria Predict; BTG Early Detection of Pancreatic Cancer; Avantect Pancreatic Cancer Test; CyPath Lung; SmartVascular DX.

These tests are listed because evidence is insufficient to demonstrate improved net health outcomes; see Background for rationale.

Some genetic testing services may be subject to contract exclusions for funded groups that have elected to exclude expanded biomarker coverage under the state biomarker mandate (RI. GL. 27-19-81). Providers should consult the member's Benefit Booklet, Evidence of Coverage, or Subscriber Agreement to determine whether the member's plan includes such exclusions and how they affect laboratory benefits.

This medical policy is provided for informational purposes only and is not a guarantee of payment. Benefits and eligibility are determined by the member's subscriber agreement, member certificate, or employer agreement, which supersede this policy. For member-specific coverage and prior authorization requirements, contact the payer's provider call center prior to ordering services.

Examples of proprietary tests referenced in this policy include: Polygenic Risk Score (various vendors; no specific CPT assigned), Thyroid GuidePx (protean biodiagnostics gene-expression profiling), APOL1 renal risk genotyping (apolipoprotein L1 variants), Oncuria Detect/Monitor/Predict (urinary protein biomarker panels), BTG Early Detection of Pancreatic Cancer, Avantect Pancreatic Cancer Test, CyPath Lung, and SmartVascular DX (immunoassay panel combined with clinical variables to report a 5-year acute coronary syndrome risk score).

Covered Indications

No indications are covered; the following tests are considered investigational and are not covered for Medicare Advantage Plans and are not medically necessary for Commercial Products when used for diagnostic, prognostic, therapeutic, or future risk assessment purposes.

Covered indications: None. No clinical indications for the tests listed in this policy meet criteria for coverage due to insufficient evidence of clinical utility.

If a separate evidence review exists for a specific test, that review supersedes this policy.

Listed tests considered investigational: Apolipoprotein L1 (APOL1) renal risk variant genotyping; Polygenic Risk Score; Thyroid GuidePx; Oncuria Detect; Oncuria Monitor; Oncuria Predict; BTG Early Detection of Pancreatic Cancer; Avantect Pancreatic Cancer Test; CyPath Lung; SmartVascular DX.

These proprietary and laboratory-developed tests lack sufficient evidence of clinical utility based on the policy overview and background.

CPT / PLA / Unlisted codes

PLA / Specific CPT codesCPTNot Covered

0355U	APOL1 (apolipoprotein L1) renal risk variants (G1, G2)
0362U	Thyroid GuidePx: gene-expression profiling via targeted hybrid capture-enrichment RNA sequencing of 82 content genes and 10 housekeeping genes (oncology, papillary thyroid cancer)
0365U	Oncuria Detect: urinary protein biomarkers with diagnostic algorithm reported as probability of harboring urothelial cancer
0366U	Oncuria Monitor: urinary analysis of 10 biomarkers with algorithm reported as probability of recurrent bladder cancer
0367U	Oncuria Predict: urinary analysis of 10 protein biomarkers with diagnostic algorithm reported as risk score for recurrence following transurethral resection
0405U	BTG Early Detection of Pancreatic Cancer: 59 methylation haplotype block markers, NGS, plasma
0406U	CyPath Lung: flow cytometry, sputum, 5 markers
0410U	Avantect Pancreatic Cancer Test: whole genome sequencing with 5-hydroxymethylcytosine enrichment; blood or plasma
0415U	SmartVascular DX: immunoassay panel combined with clinical variables to report 5-year risk score for acute coronary syndrome

Unlisted / Polygenic Risk ScoreCPTNot Covered

81479

Unlisted molecular pathology procedure (used for polygenic risk score when no CPT assigned)

Referenced Proprietary CPT CodeCPT

0415U

Cardiovascular disease (acute coronary syndrome [ACS]) risk score using multiple biomarkers and clinical variables (new code effective 10/01/2023)

Provider requirements, prior authorization, and billing guidance

Prior Authorization

Prior authorization — no prior authorization applicable per this policy

No prior authorization is required under this policy. However, prior authorization and benefit requirements may vary by contract; providers should verify member-specific benefits and any prior authorization requirements with the payer before performing services.

Prior authorization: Not required per this policy (may vary by contract)
Verify member-specific prior authorization requirements with the provider call center

Note

Prior authorization and benefit verification

Providers must verify member-specific benefits and eligibility prior to ordering tests. Benefit coverage for genetic and molecular tests varies by group and contract and is governed by the member's Benefit Booklet, Evidence of Coverage, Subscriber Agreement, and any employer agreement.

Call the provider call center for member-specific benefit and eligibility verification
Refer to the member's Benefit Booklet, Evidence of Coverage, or Subscriber Agreement for contract-specific coverage

Tests and services considered not covered

The following tests are enumerated in the policy as not covered for Medicare Advantage Plans and not medically necessary for Commercial Products due to insufficient evidence: Polygenic Risk Score (many vendor implementations), Thyroid GuidePx, APOL1 (Apolipoprotein L1) renal risk variant genotyping, Oncuria Detect / Monitor / Predict, BTG Early Detection of Pancreatic Cancer, Avantect Pancreatic Cancer Test, CyPath Lung, and SmartVascular DX.

The policy does not establish guaranteed coverage determinations; it is informational and does not guarantee payment. Provider billing and coverage decisions must reflect the member's specific subscriber or employer agreement, and services determined to be not medically necessary or non-covered may result in claim denials or member financial responsibility unless prior written agreement is obtained.

Background and policy context

Rationale: many proprietary genetic and molecular tests reach commercial availability before there is sufficient evidence of clinical validity and clinical utility to support their routine use. These assays are frequently laboratory-developed tests that must meet CLIA high-complexity requirements, yet the available evidence for meaningful impact on patient outcomes is limited or non-evaluable for the listed tests; where a separate evidence review exists for a specific test, that review supersedes this policy.

Definitions and test descriptions

Laboratory‑developed test (LDT) — definition and CLIA expectation

DefinitionLaboratory-developed test (LDT): a test developed and validated in‑house by a clinical laboratory.

Regulatory expectationLDTs must meet Clinical Laboratory Improvement Amendments (CLIA) general regulatory standards and laboratories offering LDTs must be CLIA‑licensed for high‑complexity testing.

FDA reviewTo date, the U.S. Food and Drug Administration has not required regulatory review of these tests.

Evidence statusMany proprietary LDTs are available clinically before independent evaluation; evidence of clinical validity and utility is often limited or lacking.

SmartVascular Dx — brief description

Test nameSmartVascular DX (CPT 0415U)